Innocan Pharma (INNPF) Net Income Attributable to Noncontrolling Interests (2024 - 2025)
Innocan Pharma (INNPF) reported Net Income Attributable to Noncontrolling Interests of -$140,000 for the quarter ended Dec 31, 2025, compared with $66,000 a year earlier.
Powered by 
Analysis
Innocan Pharma (INNPF) Net Income Attributable to Noncontrolling Interests (2024 - 2025) Analysis & Trends
For the year ended Dec 31, 2025, Innocan Pharma posted Net Income Attributable to Noncontrolling Interests of $783,000, down 50.2% from the prior year.
- By year, Net Income Attributable to Noncontrolling Interests came in at $1.57 million in the year ended Dec 31, 2024 (+247.8%) and $452,000 in the year ended Dec 31, 2023.
- The figure for the quarter ended Dec 31, 2025 ranks as the lowest quarterly Net Income Attributable to Noncontrolling Interests in data going back to the quarter ended Mar 31, 2024.
- Per Business Quant data, the three quarters before the quarter ended Dec 31, 2025 came in at $295,000 (quarter ended Sep 30, 2025), $275,000 (quarter ended Jun 30, 2025) and $353,000 (quarter ended Mar 31, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCI Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | - |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 2.00 Mn |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 2.00 Mn |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | -1.00 Mn |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | - |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 10.00 Mn |
| 10 | Innocan Pharma | 5.78 Mn | 1.73 Mn | 4.43 Mn | -140,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -140,000.00 |
| Sep 30, 2025 | 295,000.00 |
| Jun 30, 2025 | 275,000.00 |
| Mar 31, 2025 | 353,000.00 |
| Dec 31, 2024 | 66,000.00 |
| Sep 30, 2024 | 574,000.00 |
| Jun 30, 2024 | 619,000.00 |
| Mar 31, 2024 | 313,000.00 |
API Access
Innocan Pharma Net Income Attributable to Noncontrolling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=INNPF&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "INNPF", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=INNPF&period=max&api_key=YOUR_API_KEY");
const data = await res.json();